receptor, or a pharmaceutically acceptable salt thereof.

[0015] The present disclosure also relates to a pharmaceutical composition for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, the pharmaceutical composition including a selective S1P receptor agonist and a pharmaceutically acceptable excipient. The pharmaceutical composition encompasses a preventive or therapeutic agent for an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, the preventive or therapeutic agent including a selective S1P receptor agonist.

[0015a] In one example, the present disclosure refers to a pharmaceutical composition for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, the pharmaceutical composition comprising as an active ingredient a selective S1P receptor agonist having agonist activity at an $S1P_1$ receptor.

[0016] The present disclosure also relates to: a use of a selective S1P receptor agonist for manufacture of a pharmaceutical composition for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability; a use of a selective S1P receptor agonist for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability; a selective S1P receptor agonist

agonist to a subject. The term "subject" refers to a human or any other animal in need of the prevention or treatment, and in one example, refers to a human in need of the prevention or treatment.

[0016a] In another aspect, the present disclosure refers to use of an effective dose of a selective S1P receptor agonist having agonist activity at an $S1P_1$ receptor in the manufacture of a medicament for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability in a subject, wherein the selective S1P receptor agonist is a compound having $S1P_1$ receptor agonist activity and further having agonist activity at one or both of an $S1P_5$ receptor and an $S1P_4$ receptor, or a pharmaceutically acceptable salt thereof.

[0016b] In another example, the present disclosure refers to a selective S1P receptor agonist having agonist activity at an $S1P_1$ receptor, for use in prevention or treatment of an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability.

[0017] That is, the present disclosure includes the following items.

(1) A pharmaceutical composition for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, the pharmaceutical composition including as an active ingredient a selective S1P receptor agonist having agonist activity at an $S1P_1$ receptor.

(2) The pharmaceutical composition according to Item (1), wherein the selective S1P receptor agonist is a compound having $S1P_1$ receptor

Claims

[Claim 1] Use of an effective dose of a selective S1P receptor agonist having agonist activity at an $S1P_1$ receptor in the manufacture of a medicament for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability in a subject, wherein the selective S1P receptor agonist is a compound having $S1P_1$ receptor agonist activity and further having agonist activity at one or both of an $S1P_5$ receptor and an $S1P_4$ receptor, or a pharmaceutically acceptable salt thereof.

[Claim 2] The use according to claim 1, wherein the selective S1P receptor agonist is a compound having $S1P_1$ receptor agonist activity and further having agonist activity at an $S1P_5$ receptor, or a pharmaceutically acceptable salt thereof.

[Claim 3] The use according to any one of claims 1 to 2, wherein the selective S1P receptor agonist is a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:
5-{5-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-benzimidazole or a pharmaceutically acceptable salt thereof;
1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]methoxy}-2H-1-benzopyran-3-yl)methyl]piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof;

1-({4-[(1E)-N-{[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}ethanimidoyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid or a pharmaceutically acceptable salt thereof; 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile or a pharmaceutically acceptable salt thereof; (2Z,5Z)-5-({3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl}methylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one or a pharmaceutically acceptable salt thereof; [(3R)-7-{[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy}-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid or a pharmaceutically acceptable salt thereof; and 2-amino-2-[2-(4-{[3-(benzyloxy)phenyl]sulfanyl}-2-chlorophenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof.

[Claim 4] The use according to claim 3, wherein the selective S1P receptor agonist is 5-{5-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-benzimidazole or a pharmaceutically acceptable salt thereof.

[Claim 5] The use according to any one of claims 1 to 4, wherein the ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular

permeability is exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinopathy of prematurity, myopic choroidal neovascularization, secondary choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, neovascular glaucoma, retinitis pigmentosa, or edema caused by retinal photocoagulation.

[Claim 6] The use according to any one of claims 1 to 4, wherein the ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability is exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, or neovascular glaucoma.

[Claim 7] The use according to any one of claims 1 to 6, wherein the medicament is to be administered via intraocular injection or intravitreal injection.

[Claim 8] The use according to claim 7, wherein the medicament is to be administered via intravitreal injection.